Jenia Jenab-Wolcott, MD, PhD


Cooper University Health Care Titles

  • Hematologist/Medical Oncologist
  • Associate Director, William G. Rohrer Cancer Genetics Program

Cooper Medical School of Rowan University Titles

  • Assistant Professor of Medicine

Board Certifications

  • American Board of Internal Medicine (Hematology)
  • American Board of Internal Medicine (Medical Oncology)

Professional Type

Cooper University Physician



Education & Training

Medical SchoolTufts University School of Medicine, Boston, MA
Graduate SchoolPhD, Immunology - Tufts University School of Medicine, Boston, MA
InternshipInternal Medicine - Yale New Haven Hospital, New Haven, CT
ResidencyInternal Medicine - Yale New Haven Hospital, New Haven, CT
FellowshipHematology/Oncology - Hospital of the University of Pennsylvania, Philadelphia, PA

Special Interests

Breast cancer, gastrointestinal cancers, cancer genetics and benign blood disorders.


  • American Medical Association
  • American College of Physicians - American Society of Internal Medicine
  • American Society of Clinical Oncology
  • Society of Integrative Oncology

Awards and Honors

  • Johnson & Johnson International Health Physician Scholar Award to the Alaska Native Medical Center - 2004


Liu D, Jenab J, Rosenberg N. Kappa and lambda rearrangement occur simultaneously in transformed pre-B cells. J Immunol. 1997 Dec 15;159(12):6061-9. PMID: 9550405.

Unnikrishnan I, Radfar A, Jenab-Wolcott J, Rosenberg N. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol Cell Biol. 1999 Jul;19(7):4825-31. doi: 10.1128/mcb.19.7.4825. PMID: 10373532; PMCID: PMC84281.

Jenab-Wolcott J, Rodriguez-Correa D, Reitmair AH, Mak T, Rosenberg N. The absence of Msh2 alters abelson virus pre-B-cell transformation by influencing p53 mutation. Mol Cell Biol. 2000 Nov;20(22):8373-81. doi: 10.1128/mcb.20.22.8373-8381.2000. PMID: 11046134; PMCID: PMC102144.

Pascarella MR, McCloskey D, Jenab-Wolcott J, Vala M, Rovito M, McHugh J. Large cell neuroendocrine carcinoma of the colon: A rare and aggressive tumor. J Gastrointest Oncol. 2011 Dec;2(4):250-3. doi: 10.3978/j.issn.2078-6891.2011.026. PMID: 22811859; PMCID: PMC3397622.

Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009 Apr;9(4):507-17. doi: 10.1517/14712590902817817. PMID: 19344286.

Jenab-Wolcott J, Giantonio BJ. Antiangiogenic therapy in colorectal cancer: where are we 5 years later? Clin Colorectal Cancer. 2010 Jun;9 Suppl 1:S7-15. doi: 10.3816/CCC.2010.s.002. PMID: 20630853.

Jenab-Wolcott J, Giantonio BJ. The continuum of care in the chemotherapy approach of metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2013 Sep; 9(3): 230-241.

Jenab-Wolcott J, Giantonio BJ. (2013). Chapter 9, “Cancers of Rectum and Anal Canal”, p141-171. Molecular Pathology of Neoplastic Gastrointestinal Diseases. Editors Sepulveda A and Lynch J. Springer Science and Business Media, New York.